p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

In contrast to the highly significant changes in gene expression and pathway alterations observed in the B-cells from the untreated Eμ-TCL1 and Eμ-TCL1;p53 R172H /+ mice, gene set enrichment analysis revealed scant expression differences between treated Eμ-TCL1 and Eμ-TCL1;p53 R172H /+ malignant B-cells, with no pathway differences reaching statistical significance ( Supplementary Figure 2A ).

also in 132,142 other papers